Get the Stockscreener App
103.64
0.93%
-0.165
Celcuity Inc stock is traded at $103.64, with a volume of 18,920.
It is down -0.93% in the last 24 hours and down -2.65% over the past month.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
See More
Previous Close:
$103.80
Open:
$103.15
24h Volume:
18,920
Relative Volume:
0.02
Market Cap:
$4.78B
Revenue:
-
Net Income/Loss:
$-63.78M
P/E Ratio:
-38.67
EPS:
-2.68
Net Cash Flow:
$-53.91M
1W Performance:
+2.92%
1M Performance:
-2.65%
6M Performance:
+645.72%
1Y Performance:
+680.83%
1-Day Range:
$102.00
$104.44
1-Week Range:
$98.48
$105.68
52-Week Range:
$7.575
$112.64
Celcuity Inc Stock (CELC) Company Profile
Name
Celcuity Inc
Sector
Industry
Phone
763-392-0767
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
103.29 | 4.80B | 0 | -63.78M | -53.91M | -2.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.71 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.49 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.77 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.47 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Nov-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-22-25 | Initiated | Guggenheim | Buy |
| Jul-01-25 | Resumed | Stifel | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Feb-22-24 | Initiated | Stifel | Buy |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Oct-08-21 | Initiated | Canaccord Genuity | Buy |
| Sep-07-21 | Initiated | Jefferies | Buy |
| Jul-29-21 | Initiated | Cowen | Outperform |
| Jul-27-21 | Initiated | Needham | Buy |
| Jan-28-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| May-11-20 | Resumed | Craig Hallum | Buy |
| Nov-20-18 | Initiated | H.C. Wainwright | Buy |
View All
Celcuity Inc Stock (CELC) Latest News
What analysts say about Celcuity Inc stockWeekly Market Snapshot & You’ll Thank Yourself in 6 Months - earlytimes.in
Celcuity (CELC) Surges 662% in 2025 on Breast Cancer Treatment Trial Results - Insider Monkey
Meet the 10 Market Stars Behind Millionaire-Making in 2025 - Insider Monkey
2025’s best-performing Minnesota public company stock is a biopharmaceutical firm with no revenue - Star Tribune
Celcuity, Inc. (NASDAQ:CELC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Trading Systems Reacting to (CELC) Volatility - Stock Traders Daily
Celcuity: After Stellar 2025, I Predict More Success In 2026 And Beyond (NASDAQ:CELC) - Seeking Alpha
Celcuity (CELC)’s Clinical Success and M&A Potential Underpin Wolfe Research’s Bullish View - MSN
Celcuity Inc. Earnings Call: Strong Progress Amid Challenges - MSN
Net current asset value per share of Celcuity Inc. – GETTEX:7VR - TradingView — Track All Markets
ETFs Investing in Celcuity Inc. Stocks - TradingView — Track All Markets
Top Biotech Stocks To Add to Your WatchlistDecember 20th - MarketBeat
Does Celcuity Inc. stock trade at a discount to peersJuly 2025 Short Interest & Risk Managed Investment Signals - Улправда
Celcuity (CELC): Reassessing Valuation After New VIKTORIA-1 Breast Cancer Data Boosts Investor Interest - Sahm
Rate Hike: Why Celcuity Inc. stock could be next big winnerMarket Growth Report & Advanced Technical Analysis Signals - Улправда
How Celcuity Inc. stock reacts to job market dataBear Alert & AI Enhanced Trading Alerts - ulpravda.ru
Why Celcuity Inc. stock is trending among retail traders2025 Valuation Update & Scalable Portfolio Growth Ideas - ulpravda.ru
What valuation multiples suggest for Celcuity Inc. stockJuly 2025 Opening Moves & Stock Portfolio Risk Management - Улправда
Aug Retail: How Celcuity Inc. stock reacts to job market dataJuly 2025 Big Picture & Entry Point Strategy Guides - Улправда
(CELC) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Will Celcuity Inc. stock deliver better than expected guidanceIPO Watch & Stepwise Trade Execution Plans - Bölüm Sonu Canavarı
Why Celcuity Inc. stock is a value investor pickJuly 2025 Opening Moves & Risk Managed Investment Strategies - DonanımHaber
How interest rate cuts could boost Celcuity Inc. stockMarket Weekly Review & Growth Focused Stock Reports - DonanımHaber
Rate Cut: Why Celcuity Inc. stock could be next big winnerJuly 2025 Big Picture & AI Powered Market Trend Analysis - Улправда
Why Celcuity Inc. stock is rated strong buyTrade Performance Summary & Risk Managed Investment Entry Signals - ulpravda.ru
Aug Final Week: Why Celcuity Inc. stock could be next big winnerWeekly Trade Report & Free Low Drawdown Momentum Trade Ideas - ulpravda.ru
Fundamentals Check: Does Celcuity Inc. stock trade at a discount to peersMarket Sentiment Summary & Weekly Top Gainers Alerts - Улправда
Why Celcuity Inc. stock could be next big winnerMarket Sentiment Report & Fast Gaining Stock Reports - Улправда
Aug Sectors: How Celcuity Inc. stock reacts to job market dataJuly 2025 Analyst Calls & Long-Term Capital Growth Ideas - Улправда
How Investors Are Reacting To Celcuity (CELC) Gedatolisib’s Phase 3 Breast Cancer Data And Safety Profile - Yahoo Finance
Leerink Partners raises Celcuity stock price target to $118 on gedatolisib outlook - Investing.com Nigeria
Leerink Partners raises Celcuity stock price target to $118 on gedatolisib outlook By Investing.com - Investing.com South Africa
Celcuity (CELC): Fresh Phase 3 Breast Cancer Data Prompts Closer Look at Gedatolisib-Driven Valuation - Yahoo Finance
Did Gedatolisib’s Phase 3 PFS and Tolerability Data Just Shift Celcuity’s (CELC) Investment Narrative? - simplywall.st
Celcuity (NASDAQ:CELC) Coverage Initiated by Analysts at Wells Fargo & Company - MarketBeat
Celcuity initiated with an overweight at Wells Fargo - MSN
Celcuity (CELC) Valuation Check After Paradigm-Shifting VIKTORIA-1 Breast Cancer Data Update - Sahm
Celcuity (NASDAQ:CELC) Hits New 1-Year HighShould You Buy? - MarketBeat
Eventide Asset Management LLC Buys 123,774 Shares of Celcuity, Inc. $CELC - MarketBeat
Wells Fargo Initiates Coverage of Celcuity (CELC) with Overweight Recommendation - Nasdaq
Is CELC Stock Overpriced? - timothysykes.com
RH Posts Strong Q3 Sales, Joins Canopy Growth, Tilray Brands, Frequency Electronics And Other Big Stocks Moving Higher On Friday - Benzinga
Celcuity stock hits all-time high at 109.15 USD By Investing.com - Investing.com Canada
Celcuity stock hits all-time high at 109.15 USD - Investing.com
Celcuity downgraded to Neutral from Buy at H.C. Wainwright - MSN
Wells Fargo Initiates Celcuity With Overweight Rating, $126 Price Target - marketscreener.com
Celcuity Inc. (CELC)’s FDA NDA for Gedatolisib Accepted Under RTOR, Accelerating Review - MSN
Tracking the Top-Performing Russell 2000 Stocks Against the Zacks Rank - Finviz
Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium - The Manila Times
Celcuity Presents Updated Results from the PIK3CA Wild-Type - GlobeNewswire
Director Cashes Out: Celcuity Stock Sale Revealed! - TipRanks
Celcuity Inc Stock (CELC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.60%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):